Zhao Tianhe, Wu Lichun, Li Xinyang, Dai Huangmei, Zhang Zunzhen
Department of Environmental Health and Occupational Medicine, West China School of Public Health, Sichuan University, Chengdu, Sichuan, China.
Division of Clinical Laboratory, Sichuan Cancer Hospital, Chengdu, Sichuan, China.
Cancer Biomark. 2017 Aug 23;20(2):165-173. doi: 10.3233/CBM-170064.
Recent study has revealed that large intergenic non-coding RNA-ROR (linc-ROR) is aberrantly expressed in a number of cancers including breast cancer. However, whether circulating linc-ROR in plasma could be used for breast cancer diagnosis and dynamic monitoring is not clear.
The objective of this study is to determine if plasma linc-ROR could be applied as a biomarker for the diagnosis and dynamic monitoring of breast cancer.
We tested the expression levels of linc-ROR in 24 pairs of tissue samples and 96 plasma samples from breast cancer patients by quantitative real time-polymerase chain reaction (qRT-PCR), and analyzed the correlation between plasma linc-ROR levels and clinico-pathological characteristics. Receiver operating characteristic (ROC) curve was used to assess the diagnostic power of plasma linc-ROR, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA)153 for breast cancer. Furthermore, we explored the monitoring values of plasma linc-ROR for breast cancer by analyzing the preoperative and postoperative plasma linc-ROR levels of the same patients.
The expression levels of linc-ROR were significantly higher in breast cancer tissues and plasma than the levels in the control (P< 0.05). The linc-ROR expression levels in plasma were correlated with lymph node metastasis (P< 0.05), estrogen receptor (ER) (P< 0.05) and progesterone receptor (PR) (P< 0.05). The area under the ROC curve of plasma linc-ROR was 0.758 (sensitivity 80.0%; specificity 73.3%), which was higher than CEA and CA153 values from the same patients obtained. Combination of the linc-ROR with the conventional biomarkers might produce better diagnostic ability. Additionally, the linc-ROR expression levels of plasma in postoperative patients were lower than those in preoperative patients (P< 0.05).
Overexpressed linc-ROR may be a potential biomarker for the diagnosis and dynamic monitoring of breast cancer.
最近的研究表明，长链非编码RNA-ROR（linc-ROR）在包括乳腺癌在内的多种癌症中异常表达。然而，血浆中循环的linc-ROR是否可用于乳腺癌的诊断和动态监测尚不清楚。
本研究的目的是确定血浆linc-ROR是否可作为乳腺癌诊断和动态监测的生物标志物。
我们通过定量实时聚合酶链反应（qRT-PCR）检测了24对乳腺癌患者组织样本和96份血浆样本中linc-ROR的表达水平，并分析了血浆linc-ROR水平与临床病理特征之间的相关性。采用受试者工作特征（ROC）曲线评估血浆linc-ROR、癌胚抗原（CEA）和糖类抗原（CA）153对乳腺癌的诊断能力。此外，我们通过分析同一患者术前和术后血浆linc-ROR水平，探讨了血浆linc-ROR对乳腺癌的监测价值。
乳腺癌组织和血浆中linc-ROR的表达水平显著高于对照组（P<0.05）。血浆中linc-ROR的表达水平与淋巴结转移（P<0.05）、雌激素受体（ER）（P<0.05）和孕激素受体（PR）（P<0.05）相关。血浆linc-ROR的ROC曲线下面积为0.758（敏感性80.0%；特异性73.3%），高于同一患者的CEA和CA153值。linc-ROR与传统生物标志物联合使用可能会产生更好的诊断能力。此外，术后患者血浆中linc-ROR的表达水平低于术前患者（P<0.05）。
linc-ROR过表达可能是乳腺癌诊断和动态监测的潜在生物标志物。
